康哲药业创新药CMS-D005获临床试验批准

财中社
27 Nov 2024

财中社11月27日电康哲药业(00867)发布自愿性及业务进展公告,宣布其自主研发的创新药CMS-D005于2024年11月27日获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书。该临床试验将在中国对健康以及超重和肥胖成人受试者进行,旨在评估CMS-D005的安全性、耐受性及药代动力学和药效学特征。CMS-D005是一种高活性、高选择性的胰高血糖素样肽-1受体(GLP-1R)和胰...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10